Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Non-Current Debt: 2020-2021

  • RedHill Biopharma's Non-Current Debt rose 2.74% to $83.6 million in Q4 2021 from the same period last year, while for Dec 2021 it was $83.6 million, marking a year-over-year increase of 2.74%. This contributed to the annual value of $83.6 million for FY2021, which is 2.74% up from last year.
  • According to the latest figures from Q4 2021, RedHill Biopharma's Non-Current Debt is $83.6 million, which was up 2.74% from $81.4 million recorded in Q4 2020.
  • RedHill Biopharma's 5-year Non-Current Debt high stood at $83.6 million for Q4 2021, and its period low was $81.4 million during Q4 2020.
  • Over the past 2 years, RedHill Biopharma's median Non-Current Debt value was $82.5 million (recorded in 2020), while the average stood at $82.5 million.
  • Data for RedHill Biopharma's Non-Current Debt shows a peak YoY grew of 2.74% (in 2021) over the last 5 years.
  • Over the past 2 years, RedHill Biopharma's Non-Current Debt (Quarterly) stood at $81.4 million in 2020, then increased by 2.74% to $83.6 million in 2021.